Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Current Liabilities for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 21.21% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 21.21% year-over-year, with the annual reading at $4.2 million for FY2025, N/A changed from the prior year.
  • Total Current Liabilities for Q4 2025 was $2.6 million at Neuphoria Therapeutics, down from $5.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $5.1 million in Q3 2025, with the low at $1.6 million in Q1 2025.
  • Average Total Current Liabilities over 4 years is $2.9 million, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities increased 14.83% in 2023, then soared 100.82% in 2025.
  • Over 4 years, Total Current Liabilities stood at $2.4 million in 2022, then increased by 14.83% to $2.8 million in 2023, then fell by 22.69% to $2.1 million in 2024, then rose by 21.21% to $2.6 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.6 million, $5.1 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.